AMN Healthcare Services filings document operating results, governance matters, capital-structure disclosures, and material events for a healthcare workforce solutions company. Form 8-K reports include quarterly and annual financial results, Regulation FD investor presentation materials, board and officer matters, and amendments to corporate bylaws.
The company's proxy materials cover annual meeting voting, board composition, shareholder proposal procedures, director nomination mechanics, governance practices, performance discussion, and capital allocation priorities. Filings also disclose segment activity across Nurse and Allied Solutions, Physician and Leadership Solutions, and Technology and Workforce Solutions, along with debt, leverage, liquidity, and risk-related reporting.
AMN Healthcare Services, Inc. plans a Fifth Amendment to its Credit Agreement that extends the maturity of its secured revolving credit facility to October 2030 from February 2028 while reducing the facility size from $750.0 million to $450.0 million. The amendment also removes the ten basis point credit spread adjustment tied to the Adjusted Term SOFR Adjustment.
The Consolidated Net Leverage Ratio covenant will be revised to be no greater than 5.25 to 1.00. A new pricing tier for a Net Leverage Ratio of at least 4.25x sets margins of 2.00% for SOFR loans, 1.00% for Base Rate Loans, 2.00% for the Letter of Credit Fee and 0.35% for the Unused Fee. The administrative agent has indicated sufficient lender consents, with final documentation expected in the fourth quarter of 2025.
AMN Healthcare Services, Inc. plans a Fifth Amendment to its Credit Agreement that extends the maturity of its secured revolving credit facility to October 2030 from February 2028 while reducing the facility size from $750.0 million to $450.0 million. The amendment also removes the ten basis point credit spread adjustment tied to the Adjusted Term SOFR Adjustment.
The Consolidated Net Leverage Ratio covenant will be revised to be no greater than 5.25 to 1.00. A new pricing tier for a Net Leverage Ratio of at least 4.25x sets margins of 2.00% for SOFR loans, 1.00% for Base Rate Loans, 2.00% for the Letter of Credit Fee and 0.35% for the Unused Fee. The administrative agent has indicated sufficient lender consents, with final documentation expected in the fourth quarter of 2025.
AMN Healthcare Services, Inc. plans a Fifth Amendment to its Credit Agreement that extends the maturity of its secured revolving credit facility to October 2030 from February 2028 while reducing the facility size from $750.0 million to $450.0 million. The amendment also removes the ten basis point credit spread adjustment tied to the Adjusted Term SOFR Adjustment.
The Consolidated Net Leverage Ratio covenant will be revised to be no greater than 5.25 to 1.00. A new pricing tier for a Net Leverage Ratio of at least 4.25x sets margins of 2.00% for SOFR loans, 1.00% for Base Rate Loans, 2.00% for the Letter of Credit Fee and 0.35% for the Unused Fee. The administrative agent has indicated sufficient lender consents, with final documentation expected in the fourth quarter of 2025.
AMN Healthcare Services, Inc. plans a Fifth Amendment to its Credit Agreement that extends the maturity of its secured revolving credit facility to October 2030 from February 2028 while reducing the facility size from $750.0 million to $450.0 million. The amendment also removes the ten basis point credit spread adjustment tied to the Adjusted Term SOFR Adjustment.
The Consolidated Net Leverage Ratio covenant will be revised to be no greater than 5.25 to 1.00. A new pricing tier for a Net Leverage Ratio of at least 4.25x sets margins of 2.00% for SOFR loans, 1.00% for Base Rate Loans, 2.00% for the Letter of Credit Fee and 0.35% for the Unused Fee. The administrative agent has indicated sufficient lender consents, with final documentation expected in the fourth quarter of 2025.
Whitney M. Laughlin, Chief Legal Officer of AMN Healthcare Services, reported on Form 4 that 483 restricted stock units (RSUs) vested on September 15, 2025, converting into 483 shares of AMN common stock. Of those shares, 118 were sold or withheld at $18.25 per share to satisfy tax withholding, leaving the reporting person with 16,732 shares beneficially owned after the transactions. The RSUs were originally granted under the AMN Healthcare 2017 Equity Plan on September 15, 2023 and vest in three annual tranches; the units have no expiration date. The report is a routine insider equity vesting and tax-withholding transaction rather than a discretionary open-market purchase or sale.
Whitney M. Laughlin, Chief Legal Officer of AMN Healthcare Services, reported on Form 4 that 483 restricted stock units (RSUs) vested on September 15, 2025, converting into 483 shares of AMN common stock. Of those shares, 118 were sold or withheld at $18.25 per share to satisfy tax withholding, leaving the reporting person with 16,732 shares beneficially owned after the transactions. The RSUs were originally granted under the AMN Healthcare 2017 Equity Plan on September 15, 2023 and vest in three annual tranches; the units have no expiration date. The report is a routine insider equity vesting and tax-withholding transaction rather than a discretionary open-market purchase or sale.
FMR LLC and its chair & CEO Abigail P. Johnson have filed a Schedule 13G disclosing a 6.2 % passive stake in AMN Healthcare Services, Inc. (AMN) as of 30 Jun 2025. The position equals 2,391,522.85 common shares.
- Sole voting power: 2,388,349 shares
- Sole dispositive power: 2,391,522.85 shares
- Shared voting/dispositive power: 0 shares
The filing is made under Rule 13d-1(b) by a parent holding company/control person. An affiliated fund, Fidelity Small Cap Value Fund, holds 1,980,849 shares (5.2 %) within the aggregate amount. The signatory certifies the stake is held in the ordinary course of business without intent to influence control.
While no purchase history or cost basis is provided, FMR’s >5 % ownership signals continued institutional interest in AMN. No other material events, financial results, or strategic actions are disclosed.